This patent teaches a new way of cloning, including for the generation of embryonic stem cells, by selecting oocytes at a specific cell stage called telophase.
It is not good enough to encapsulate stem cells for therapeutic use, since the stem cells will have to be transported to the hospital or institution where they are needed. This patent covers methods of cryopreserving cells that have been encapsulated so that they may be shipped to the region of need.
This patent covers VCAM positive bone marrow stromal cells. These are the cells that support hematopoietic stem cell proliferation. Do mesenchymal stem cells have VCAM on them??
This patent discloses compounds that can be added to a culture of embryonic stem cells so as to selectively kill non-embryonic stem cells.
This patent provides kits for purifying out of a human-SCID mouse cells of human origin.
This and patent #5,876,956 are licensed to the company Aldagen (2810 Meridian Parkway Suite 148 Durham, NC 27713 919-484-2571) that is actually purifying stem cells using this method for clinical trials (for example: Intramyocardial Injection of Autologous Aldehyde Dehydrogenase-Bright Stem Cells for Therapeutic Angiogenesis at Texas Heart: Oct 5, 2006). The patent covers purifying stem...
This patent covers methods of storing neural stem cells and neural cells that have been differentiated from stem cells. This patent covers not only human but also porcine cells. The assignee company was at one time performing clinical trials with encapsulated porcine neural cells in patients.
This patent covers methods of preserving neural stem cells and various types of neuronal cells so that they may be transported for use in treatment of neurological disorders. One of the drawbacks of such cell therapy is the issue of rejection by the allogeneic immune system, this has been addressed in studies using encapsulation, or using stereotactic implantation into the brain, since the...
This patent seems to cover methods of purifying and expanding hematopoietic stem cells by transfecting said stem cells with a drug efflux pump. It is not clear if the patent calls for administration of a cytotoxic agent to selectively kill non-stem cells, or if it is inherently the property of the efflux pumps to increase stem cell viability. The patent has 2 independent...
Methods and devices are disclosed that enable efficient collection and storage of cord blood.